I am kind of in between on this one (Viracyte merger).
Although I have stated several times I would be against and would vote NO on ANY buyout from ANY Big Pharma company, because for the obvious reason that MRKR will be worth much more over the long term if they remain independent, my decision on a Viracyte merger would depend upon the realization of who needs who and how much $'s.
If Viracyte accepts that they need us more than we need them and will therefore accept a smaller merger price, then I think both can win.
Viracyte gets a source of future cash access they will need, Viracyte gets access to our major investors (NEA/Baker/etc), Viracyte gets a more secure future.
MRKR gets a larger pipeline (slightly, as 2 of 4 are still pre-clinical), MRKR gets a New Therapy to add to their lineup (that also has very promising potential) which can be very financially lucrative.
MRKR gets a new therapeutic line that is going after several indications.
MRKR and Viracyte BOTH get a Happier combined family (who really already are the same family members).
It all depends on the $$$$$$$$$$$ and the realization that you have to spend money to make money.
A merger now will cost MRKR a BIT up front but will pay off with increased $$$$ in the future.
If Viracyte thinks they are currently worth 100 million, they can jump in a lake and stay private.
If Viracyte realizes all the benefits to THEM and are willing to value themselves at 25 million or < … welcome to the MRKR family.
News 
Market Data 
Discover 
